Top brokers name 3 ASX shares to buy

Wesfarmers Ltd (ASX:WES) shares are one of three that brokers have named as buys this week…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

a woman

Many of Australia's top brokers have been busy adjusting their financial models again, leading to the release of a large number of broker notes this week.

Three buy ratings that have caught my eye are summarised below. Here's why brokers think these ASX shares are in the buy zone:

Galaxy Resources Limited (ASX: GXY)

According to a note out of Citi, its analysts have retained their buy rating but trimmed the price target on this lithium miner's shares to $2.70 following the release of its first quarter update. Citi appears a touch disappointed with Galaxy's higher costs and has revised its forecasts accordingly. Furthermore, although the company revealed that it has been unable to find a partner to develop its Sal de Vida asset with, the broker believes Galaxy has the means to fund it itself. Though, it notes that this is a risky option for the company. Whilst I think Galaxy's shares look very cheap, I wouldn't be a buyer until lithium prices reach an inflection point.

ResApp Health Ltd (ASX: RAP)

Analysts at Morgans have retained their add rating and 19 cents price target on this digital health company's shares after it released positive top-line results from its Australian Breathe Easy adult prospective, double-blind clinical study. ResApp's smartphone-based algorithms were found to accurately diagnose all respiratory diseases included in the study. Morgans sees this as a big positive as the adult respiratory market is upwards of three times larger than the paediatric market. I was impressed with ResApp's results, but I feel it is a little too soon to make an investment.

Wesfarmers Ltd (ASX: WES)

A note out of the Macquarie equities desk reveals that its analysts have retained their outperform rating and $37.13 price target on this conglomerate's shares. According to the note, the broker believes the housing market is stabilising, which is good news for its key Bunnings business at a time when it is expanding its product range into new categories. I agree with Macquarie on Wesfarmers and would class its shares as a buy.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Wesfarmers Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »